Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Juejun Gong
Institutions:
Central Hospital of Wuhan,
Huazhong University of Science and Technology
Observed institutions:
Central Hospital of Wuhan,
Tongji Hospital,
Huazhong University of Science and Technology
ORCID:
0000-0002-5338-0188
Observed ORCID:
0000-0002-5338-0188
OpenAlex ID:
A5061661472
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study
2023
·
Ping Peng
, Juejun Gong
, et al.
·
Radiotherapy and Oncology
·
88
PDF
The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
2022
·
Shiyu Li
, Shuangli Zhu
, et al.
·
Biomedicine & Pharmacotherapy
·
29
PDF
GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis
2021
·
Yujie Zhang
, Yuxin Zhang
, et al.
·
Oncogene
·
10
PDF
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
2020
·
Juejun Gong
, Li Zhang
·
Current Opinion in Oncology
·
8
An autophagy-related diagnostic biomarker for uterine fibroids: FOS
2023
·
Lei Cai
, Jie Li
, et al.
·
Frontiers in Medicine
·
4
Comprehensive analysis of the expression and prognosis for RAI2: A promising biomarker in breast cancer
2023
·
Ying Jiao
, Shiyu Li
, et al.
·
Frontiers in Oncology
·
2
Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.
2022
·
Li Zhang
, Ping Peng
, et al.
·
Journal of Clinical Oncology
·
2
Early radiotherapy delays acquired gefitinib resistance in EGFR-mutant NSCLC by suppressing c-FOS-associated survival signaling
2026
·
Lin Peng
, Juejun Gong
, et al.
·
Respiratory Research
Show more works
View as search
Works count:
8
Citation count:
143
H-index:
4
I10-index:
3
Year
Topic
Type